Advanced Hematology System Allows Labs to Process Up To 119 Complete Blood Count Results per Hour

Complete blood counts (CBCs) are frequently requested in healthcare for screening various disorders like infections, anemia, immune system diseases, and blood cancers. Now, the U.S. Food and Drug Administration's (FDA) clearance for an advanced hematology system paves the way for laboratories throughout the U.S. to run CBCs in the most efficient manner possible.

Abbott (Lake Forest, IL, USA) has secured U.S. FDA approval for its state-of-the-art Alinity h-series hematology system. This system can seamlessly integrate into the existing Alinity lab systems set up across the U.S., enhancing the capabilities of these laboratories. As a result, hospitals can more readily execute CBCs, which are among the top-requested tests for patients. The Alinity h-series system offers several advantages for laboratories including the ability to process up to 119 CBC results per hour which is among the fastest on the market and the requirement for less floor space, which is critical for labs to maximize resources and operations.

The Alinity h-series boasts of the Alinity hq, an automated blood analyzer, and the Alinity hs, a combined slide creator and stainer. A standout feature of the Alinity hq is its innovative MAPS™ technology that utilizes light scattering to distinguish cellular features and better recognize different blood cells. With the Alinity h-series, Abbott now offers one of the broadest laboratory diagnostic systems, offering an extensive range of tests for timely and efficient patient care. U.S. labs and hospitals will find it easy to incorporate the Alinity h-series hematology system into their primary operations with minimal effort and training for their staff. This ease of integration is crucial for labs grappling with time and resource constraints. In the U.S., the Alinity portfolio now spans the Alinity h-series (hematology), Alinity ci (clinical chemistry and immunoassay), Alinity m (molecular), Alinity s (transfusion), and the point-of-care i-STAT Alinity.

“U.S. healthcare systems have experienced significant resource constraints and rapidly shifting dynamics post-pandemic,” said Louis Morrone, executive vice president for Abbott’s core diagnostics business. “The Alinity h-series system, as with the entire suite of Alinity products, was developed to transform the way laboratories run tests so they can focus on their most important mission: the delivery of patient care.”

Related Links:
Abbott

Visit expo >

Gold Member

Fully Automated Cell Density/Viability Analyzer

BioProfile FAST CDV

Verification Panels for Assay Development & QC
Seroconversion Panels

New

Vaginitis Test

Allplex Vaginitis Screening Assay

New

Bordetella Pertussis Molecular Assay

Alethia Pertussis